Thoracic Malignancies
Beyond lung carcinoma, thoracic oncology includes mesothelioma, thymic tumours and mediastinal malignancies — uncommon diseases where accurate pathological classification carries particular weight.
Disease categories
Major disease categories
- Pleural mesothelioma
- Thymoma and thymic carcinoma
- Mediastinal germ cell tumours
- Neuroendocrine thoracic tumours
Molecular
Molecular considerations
BAP1, NF2 and CDKN2A alterations are described in mesothelioma. Thymic tumours have a distinct and less well-characterised molecular landscape.
Markers commonly discussed in thoracic malignancies
- BAP1
- NF2
- CDKN2A
- PD-L1
Not exhaustive, and not every marker is assessed in every patient. Which of these is relevant depends on the individual case and should be discussed with the treating team.
Testing
Genomic testing considerations
Profiling is discussed in advanced disease, with recognition that the actionable yield differs from that in lung carcinoma.
Germline
Germline considerations
Germline BAP1 assessment is considered in mesothelioma where the clinical picture suggests it.
Molecular monitoring
ctDNA and liquid biopsy considerations
ctDNA use in these diseases is largely investigational.
Single-cell & computation
Single-cell and algorithmic approaches
Single-cell analysis in thoracic malignancy is used to study resistance as it emerges — separating a resistant subclone from the bulk population before it dominates, and characterising the immune contexture that bulk profiling obscures. Single-cell DNA sequencing can establish whether a resistance alteration is present in a minority of cells at baseline rather than acquired later. Algorithmic work includes fusion detection from RNA, subclonal reconstruction across serial samples, and classifiers that distinguish histological transformation from acquired resistance.
Decisions
Treatment decision questions
Questions worth raising with a treating team when a decision is being made:
- Is the pathological diagnosis secure, and has it been reviewed?
- Has molecular profiling been considered?
Resistance
Resistance and recurrence questions
- Has the diagnosis been revisited if disease behaviour is atypical?
Trials
Clinical trial considerations
Trials in these diseases are fewer, and identifying relevant ones often requires wider geographic search.
When a precision oncology review may help
A review is most useful where the standard pathway has been exhausted or where the picture is more complicated than a protocol accounts for — rare presentations, treatment resistance, complex or apparently contradictory molecular findings, or a decision between several defensible options.
The output is a structured analysis and a set of questions for the treating team. It is not treatment, and it does not replace the treating oncologist.